Typically considered to be cell surface sensors of extracellular signals, heterotrimeric GTP-binding protein (G protein)-coupled receptors (GPCRs) control many pathophysiological processes and are the target of 30% of therapeutic drugs. Activated receptors redistribute to endosomes, but researchers have yet to explore whether endosomal receptors generate signals that control complex processes in vivo and are viable therapeutic targets. We report that the substance P (SP) neurokinin 1 receptor (NK 1 R) signals from endosomes to induce sustained excitation of spinal neurons and pain transmission and that specific antagonism of the NK 1 R in endosomes with membrane-anchored drug conjugates provides more effective and sustained pain relief than conventional plasma membrane-targeted antagonists. Pharmacological and genetic disruption of clathrin, dynamin, and b-arrestin blocked SP-induced NK 1 R endocytosis and prevented SP-stimulated activation of cytosolic protein kinase C and nuclear extracellular signal-regulated kinase, as well as transcription. Endocytosis inhibitors prevented sustained SP-induced excitation of neurons in spinal cord slices in vitro and attenuated nociception in vivo. When conjugated to cholestanol to promote endosomal targeting, NK 1 R antagonists selectively inhibited endosomal signaling and sustained neuronal excitation. Cholestanol conjugation amplified and prolonged the antinociceptive actions of NK 1 R antagonists. These results reveal a critical role for endosomal signaling of the NK 1 R in the complex pathophysiology of pain and demonstrate the use of endosomally targeted GPCR antagonists.
INTRODUCTION
Whereas acute pain allows avoidance of injury and is essential for survival, chronic pain accompanies disease (for example, inflammatory diseases and neuropathies) and therapy (for example, chemotherapy), afflicts 20% of individuals at some point of their lives, and is a major cause of suffering (1) . The mechanisms that underlie the transition between acute (physiological) and chronic (pathological) pain and that sustain chronic pain are unknown. Current therapies for chronic pain are often ineffective or produce unacceptable side effects. The opioid epidemic, a leading cause of medication-induced death, highlights the need for improved pain therapy (2) .
With almost 1000 members in humans, heterotrimeric GTPbinding protein (G protein)-coupled receptors (GPCRs) are the largest receptor family, participate in most physiological and pathophysiological processes, are the target of~30% of therapeutic drugs (3) , and control all steps of pain transmission (1, 4) . GPCRs at the peripheral terminals of primary sensory neurons detect ligands from inflamed and injured tissues, and GPCRs control the activity of second-order spinal neurons that transmit pain signals centrally. Although GPCRs are a major therapeutic target for chronic pain, most GPCR-targeted drugs for pain have failed in clinical trials, often for unknown reasons (4, 5) .
GPCRs are conventionally viewed as cell surface receptors that detect extracellular ligands and couple to G proteins, which trigger plasma membrane-delimited signaling events (second messenger formation, growth factor receptor transactivation, and ion channel regulation). Activated GPCRs associate with b-arrestins (bARRs), which uncouple receptors from G proteins and terminate plasma membrane signaling. bARRs also couple receptors to clathrin and adaptor protein-2 and convey receptors and ligands to endosomes (6) . Once considered merely a conduit for GPCR trafficking, endosomes are a vital site of signaling (4, 7, 8) . bARRs recruit GPCRs and mitogen-activated protein kinases to endosomes and thereby mediate endosomal GPCR signaling (9, 10) . Some GPCRs in endosomes activate Ga s G proteins, suggesting endosomal cyclic adenosine monophosphate (cAMP)-dependent signaling (11, 12) . GPCR/G protein/bARR complexes also contribute to sustained signaling by internalized receptors (13) . Although a growing number of GPCRs can signal from endosomes, the mechanisms and outcomes of endosomal signaling are incompletely understood, and its relevance to complex pathophysiological processes in vivo is unexplored. Drug discovery programs aim to identify ligands for cell surface GPCRs, and whether endosomal GPCRs are a therapeutic target remains to be determined.
We examined the contribution of endocytosis of the neurokinin 1 receptor (NK 1 R) to substance P (SP)-mediated nociception. Painful stimuli release SP from the central projections of primary sensory neurons in the dorsal horn of the spinal cord, where SP induces endocytosis of the NK 1 R in second-order neurons, which integrate nociceptive signals (5, 14) . The NK 1 R may also be internalized in pain-sensing regions of the brain of patients with chronic pain (5, 15) . We hypothesized that endosomal signaling is a critical but unappreciated contributor to pain transmission and that targeting NK 1 R antagonists to sites of endosomal signaling might provide an effective route to pain relief. Thus, the clinical failure of conventional NK 1 R antagonists for the treatment of chronic pain and other chronic conditions associated with NK 1 R endocytosis (5) might relate to their inability to target and antagonize the NK 1 R within multiprotein signalosomes of acidified endosomes.
RESULTS
Clathrin, dynamin, and bARRs mediate NK 1 R endocytosis To quantify NK 1 R endocytosis, we used bioluminescence resonance energy transfer (BRET) to assess NK 1 R proximity to bARRs and resident proteins of plasma membranes (KRAS) and early endosomal membranes (RAB5A) in human embryonic kidney (HEK) 293 cells (fig. S1A). SP (1 or 10 nM) increased NK 1 R-RLUC8/bARR1/2-yellow fluorescent protein (YFP) BRET ( fig. S1 , B and C), which is consistent with bARR-mediated NK 1 R endocytosis (16) . SP decreased NK 1 R-RLUC8/KRAS-Venus BRET and concomitantly increased NK 1 R-RLUC8/ RAB5A-Venus BRET ( fig. S1 , D to G), indicating NK 1 R endocytosis. The dynamin inhibitor Dyngo-4a (Dy4) (17) , the clathrin inhibitor Pitstop-2 (PS2) (18) , and a dominant-negative version of dynamin (K44E) (19) inhibited NK 1 R endocytosis, whereas inactive analogs (Dy4 inact and PS2 inact) and wild-type (WT) dynamin had no effect. Dynamin K44E increased the NK 1 R-RLUC8/bARR1/2-YFP BRET, suggesting that dynamin-dependent translocation of the NK 1 R/bARR from the plasma membrane to endosomes initiates NK 1 R/bARR dissociation (fig. S1H). Dy4 and PS2 also inhibited endocytosis of fluorescent Alexa Fluor 568-SP in HEK-NK 1 R cells, causing retention in punctate structures ( fig. S1I ). These structures may represent ligand/receptor clusters in invaginated pits in cells treated with Dy4 or at the plasma membrane in cells treated with PS2. Thus, bARRs, clathrin, and dynamin mediate SPinduced NK 1 R endocytosis.
NK 1 R endocytosis mediates SP signaling in subcellular compartments
To study the link between GPCR endocytosis and signaling in subcellular compartments with high spatiotemporal fidelity, we expressed, in HEK293 cells, the NK 1 R and fluorescence resonance energy transfer (FRET) biosensors for cytosolic (CytoEKAR) or nuclear (NucEKAR) extracellular signal-regulated kinase (ERK) activity, plasma membrane (pmCKAR) or cytosolic (CytoCKAR) protein kinase C (PKC) activity, and plasma membrane (pmEpac2) or cytosolic (CytoEpac2) cAMP ( fig.  S2A ) (20) . SP (1 nM) induced a gradual and sustained activation of nuclear ERK (Fig. 1 , A to C) and a rapid and sustained activation of cytosolic PKC (Fig. 1, D to F) and cAMP ( (Fig. 1 , A to C), cytosolic PKC (Fig. 1, D to F) , and cytosolic cAMP (Fig. 1, G to I (Fig. 1, J to L) . Dynamin K44E did not prevent SP stimulation of cytosolic ERK but caused the response to become sustained when compared to dynamin WT ( fig. S2, H to J) . Knockdown of dynamin-1 and clathrin heavy chain with small interfering RNA (siRNA) (fig. S2, K and L) prevented SP activation of nuclear ERK (Fig. 1, M  and N) .
Transcription is a major endpoint of GPCR signaling, including activation of nuclear ERK. The b 2 -adrenergic receptor signals from endosomes to regulate transcription (21) . To investigate the contribution of NK 1 R endocytosis to SP-stimulated transcription, we expressed in HEK-NK 1 R cells a reporter encoding secreted alkaline phosphatase (SEAP) under control of the serum response element (SRE) transcription factor. SP (10 nM) stimulated SRE-SEAP secretion after 4 and 24 hours, indicating stimulated transcription (Fig. 1O) . Dynamin K44E abolished SP-stimulated transcription at both times. Dynamin K44E reduced the efficacy but not the potency of SP-induced transcription, measured after 24 hours ( fig. S2M ). Thus, NK 1 R endocytosis is required for SP stimulation of transcription.
We have previously shown that bARRs mediate NK 1 R endosomal signaling and nuclear ERK activation (9, 22, 23) . To examine the contribution of G proteins to endosomal NK 1 R signaling, we used BRET to study SP-induced trafficking of Ga q subunits to early endosomes containing RAB5A. SP (0.1 to 10 nM) decreased NK 1 R-RLUC8/ KRAS-Venus and increased NK 1 R-RLUC8/RAB5A-Venus BRET, demonstrating endocytosis, and decreased Ga q -RLUC8/Gg 2 -Venus BRET, consistent with G protein activation (Fig. 2, A to C, and fig.  S3 , A to C). SP increased Ga q -RLUC8/RAB5A-Venus BRET, which indicates Ga q translocation to early endosomes that contain the internalized NK 1 R (Fig. 2D and fig. S3D ). In SP-stimulated cells, NK 1 Rimmunoreactivity (IR) and Ga q -IR colocalized with early endosomal antigen 1 (EEA1)-IR (Fig. 2 , E and F); IR was detected using immunofluorescence and super-resolution microscopy.
The Ga q inhibitor UBO-QIC prevented SP activation of nuclear ERK (Fig. 2G and fig. S3E ), which also depends on bARRs and PKC but not on epidermal growth factor receptor transactivation (9, 22, 23) . UBO-QIC, the phospholipase C (PLC) inhibitor U73122, and the Ca 2+ chelator EGTA prevented activation of cytosolic PKC (Fig. 2H and  fig. S3F ), which is consistent with a Ga q , PLC, and Ca
2+
-dependent PKC pathway. UBO-QIC, the PKC inhibitor GF109203X, and EGTA, but not the Ga s inhibitor NF449, prevented SP generation of cytosolic cAMP ( Fig. 2I and fig. S3G ), supporting a role for Ga q -mediated activation of Ca 2+ -dependent PKC in the generation of cAMP. UBO-QIC did not affect NK 1 R endocytosis ( fig. S3H ). In addition to inhibiting PKCa (4% control), GF109203X (Bis-1) also inhibits other kinases (24) , which may also contribute to SP signaling. These results support the hypothesis that SP and the NK 1 R signal from endosomes by Ga q -mediated mechanisms to activate nuclear ERK and cytosolic PKC and cAMP.
Endocytosis mediates sustained SP-evoked excitation of spinal neurons
The NK 1 R mediates nociceptive transmission in second-order spinal neurons, where painful stimuli induce SP release, NK 1 R endocytosis, and ERK activation (5, 14, 25) . SP causes persistent NK 1 R-dependent excitation of spinal neurons by unknown mechanisms (26) . To evaluate whether NK 1 R endosomal signaling mediates this sustained excitation, we made cell-attached patch clamp recordings from NK 1 R-positive neurons in lamina I of the dorsal horn in slices of rat spinal cord. SP (1 mM, 5 min) stimulated NK 1 R-IR endocytosis in spinal neurons (Fig. 3, A and B, and movies S1 to S4). Brief exposure to SP (1 mM, 2 min) triggered rapid-onset action potential firing that was sustained after washout ( Fig. 3 , C to E). Dy4 but not Dy4 inact inhibited NK 1 R endocytosis. Dy4 did not affect the initial onset of SP-induced firing but prevented the sustained response, reducing both the firing rate and firing time, whereas Dy4 inact had no effect. The SP-induced firing rate (events per 2 min, normalized to rate at 2 min) was 342.1 ± 120.7 with Dy4 and 569.0 ± 187.6 with Dy4 inact [P < 0.05, analysis of variance (ANOVA), Sidak's test].
To define the signaling pathway that mediates SP-evoked excitation of spinal neurons, slices were preincubated with inhibitors of mitogenactivated protein kinase kinase (MEK) (U0126), PKC (GF109203X), or vehicle (control). U0126 inhibited the SP-induced firing time of lamina I neurons by 67.5 ± 8.3% (control: 10.01 ± 1.8 min, n = 10 cells from eight rats; U0126: 3.2 ± 0.8 min, n = 6 cells from six rats; P < 0.05, ANOVA, Dunn's test) (Fig. 3 , F to H). GF109203X reduced SP-induced firing time of lamina I neurons by 56.8 ± 8.2% (control: 10.01 ± 1.8 min, n = 10 cells from eight rats; GF109203X: 4.33 ± 0.82 min, n = 7 cells from four rats; P < 0.05, ANOVA, Dunn's test). U0126 and GF109203X reduced the number of SP-stimulated action potentials by 84 ± 5% and 61 ± 15%, respectively, compared to controls.
Dy4 did not affect the generation of excitatory postsynaptic currents (EPSCs) in lamina I/II o neurons in response to primary afferent stimulation ( Clathrin, dynamin, and bARRs mediate NK 1 R endocytosis and nociception in vivo To determine the involvement of dynamin and clathrin in NK 1 R endocytosis in vivo, we injected Dy4, PS2, inactive analogs, or vehicle intrathecally (L3/L4) to rats. After 30 min, vehicle or capsaicin was administered by intraplantar injection. The spinal cord was removed 10 min later, and the NK 1 R was localized by immunofluorescence and confocal microscopy. In vehicle-treated control rats, the NK 1 R-IR was mostly at the plasma membrane of lamina I neurons (% NK 1 R-IR within 0.5 mm of plasma membrane, 80.7 ± 1.6; n = 3 rats, 6 neurons analyzed per rat) (Fig. 4 , A and C, and movie S5). Intraplantar injection of capsaicin stimulated NK 1 R endocytosis (42.1 ± 5.6; P = 0.0027 to control, Student's t test) (movie S6). Intrathecal injection of Dy4 or PS2, but not inactive analogs, inhibited capsaicin-stimulated NK 1 R endocytosis [Dy4 (59.6 ± 0.2) versus Dy4 inact (49.9 ± 0.8), P = 0.0004 (Student's t test); PS2 (69.0 ± 1.1) versus PS2 inact (51.9 ± 1.3), P = 0.0135 (Student's t test)] (movies S7 to S10 and Fig. 4 , A and C). Painful peripheral stimuli activate ERK in NK 1 R-expressing spinal neurons, which contributes to hyperalgesia (25) . Intraplantar capsaicin stimulated ERK phosphorylation in lamina I/II dorsal horn neurons (Fig. 4 , B and D). Dy4 or PS2 prevented capsaicin-stimulated ERK activation in spinal neurons. Thus, painful stimuli induce clathrin-and dynamin-dependent NK 1 R endocytosis in spinal neurons, which is required for ERK signaling.
Does NK 1 R endocytosis in spinal neurons mediate pain transmission? To evaluate the importance of the NK 1 R, clathrin, and dynamin for nociception, we injected vehicle, NK 1 R antagonist SR140,333 (27) , Dy4, PS2, or inactive analogs intrathecally (L3/L4) to mice. After 30 min, vehicle or capsaicin was administered by intraplantar injection into one hindpaw. Withdrawal responses were measured to stimulation of the plantar surface of the ipsilateral (injected) and contralateral (noninjected) hindpaws with von Frey filaments, and edema was assessed by measuring thickness of the ipsilateral paw. In vehicle (intrathecal)-treated mice, capsaicin caused mechanical allodynia and edema for 4 hours. SR140,333 caused a partial and transient inhibition of capsaicin-induced allodynia, whereas Dy4 and PS2, but not inactive analogs, caused a large and sustained inhibition of allodynia (Fig. 4E and fig. S4A ). Paw edema was unaffected, confirming that after intrathecal injection, the drugs act locally in the spinal cord ( fig. S4B ).
Dy4 and PS2 did not affect withdrawal responses of the contralateral paw or rotarod latency, suggesting normal motor behavior (Fig. 4 , F and G). Intrathecal Dy4 also inhibited capsaicin-evoked mechanical allodynia in rat, which supports a role for dynamin in nociception in different species ( fig. S4C ).
Intrathecal injection of dynamin-1 siRNA knocked down dynamin-1-IR ( fig. S4D ) and inhibited capsaicin-evoked allodynia after 24 and 48 hours in mice (Fig. 4H and fig. S4E ). Intrathecal bARR1/2 siRNA knocked down bARR1/2 mRNA ( fig. S4F ) and inhibited capsaicin-evoked allodynia at 36 hours (Fig. 4I) . siRNAs did not affect withdrawal responses of the contralateral paw ( fig. S4 , G and H), consistent with normal motor function.
Endocytosis and subsequent recycling mediate resensitization and sustained signaling of several GPCRs, including the NK 1 R (28). Thus, the antinociceptive actions of endocytic inhibitors could be due to disrupted resensitization of plasma membrane signaling rather than to impaired endosomal signaling. Endothelin-converting enzyme-1, which is coexpressed with the NK 1 R in spinal neurons (22) , degrades SP in endosomes and thereby promotes recycling and resensitization of the NK 1 R (29). However, intrathecal injection of SM-19712, an inhibitor of endothelin-converting enzyme-1 that prevents NK 1 R recycling and resensitization (29) , had no effect on capsaicin-induced allodynia (Fig.  4J) . These results suggest that the analgesic actions of endocytic inhibitors are unrelated to disrupted resensitization. Consistent with a role for NK 1 R endocytosis and bARRs in SP-evoked nuclear ERK signaling (9), intrathecal MEK inhibitor U0126 inhibited capsaicin-evoked allodynia (Fig. 4K) (25) .
The effects of inhibitors of dynamin and clathrin on noninflammatory and inflammatory pain were examined. Intrathecal injection of Dy4 and PS2 blunted both the early (noninflammatory) and late (inflammatory) phases of the nocifensive response to intraplantar formalin (Fig. 4L) . When injected intrathecally 36 hours after intraplantar injection of complete Freund's adjuvant (CFA), which causes sustained inflammatory pain, inhibitors of dynamin and clathrin reversed preexisting mechanical hyperalgesia (Fig. 4M) . The NK 1 R was robustly internalized in spinal neurons of mice after intraplantar injection of capsaicin, formalin, and CFA ( fig. S5 , A to D). Intrathecal injection of Dy4 prevented capsaicin-and formalininduced NK 1 R endocytosis and reversed CFA-induced NK 1 R endocytosis. These results suggest that clathrin and dynamin mediate pain-evoked endocytosis of NK 1 R in spinal neurons, which is required for nociception.
Disruption of NK 1 R/bARR interactions inhibits NK 1 R endocytosis and nociception in vivo To substantiate involvement of NK 1 R endocytosis in nociception, we devised a pharmacological approach to inhibit NK 1 R/bARR interactions and NK 1 R endocytosis. G protein receptor kinases (GRKs) phosphorylate S/T-rich regions in the C terminus of GPCRs, which interact with bARRs ( 30). A deletion mutant NK 1 Rd311 lacks the C terminus and corresponds to a naturally occurring NK 1 R variant (Fig. 5A) (5) . NK 1 Rd311 was normally expressed at the plasma membrane of HEK293 cells but did not associate with bARRs or internalize (Fig. 5, B and C, and fig. S6 , A to C). In HEK-NK 1 Rd311 cells, SP stimulated cytosolic but not nuclear ERK and did not affect transcription activity, consistent with endocytosisdependent nuclear ERK signaling and transcription (Fig. 5, D and E) . Peptides corresponding to predicted phosphorylation sites in the C terminus of mouse NK 1 R were conjugated to membrane-penetrating Tat peptide (Fig. 5A) . A combination of three peptides inhibited SP-induced NK 1 R-RLUC8/bARR2-YFP BRET and prevented SP-induced NK 1 R endocytosis, compared to a control peptide, suggesting effective disruption of NK 1 R/bARR interactions (Fig. 5, F and G) . When injected intrathecally, inhibitors of NK 1 R/bARR interactions suppressed capsaicin-evoked allodynia and formalin-induced nociceptive behavior and reversed CFAinduced hyperalgesia (Fig. 5, H to J) . Together, these results support a role for bARR-mediated NK 1 R endocytosis and endosomal signaling in nociception.
Lipid conjugation delivers NK 1 R antagonists to endosomes and selectively blocks sustained endosomal signals We observed that clathrin, dynamin, and bARR inhibitors and siRNA, including selective inhibitors of NK 1 R/bARR interactions, suppress (M) von Frey withdrawal responses of the CFA-injected paw. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, to control. Student's t test (C and D); ANOVA, Dunnett' s test (E to M).
SP-induced NK 1 R endocytosis, compartmentalized signaling, transcription, and neuronal excitability, and have antinociceptive actions. These findings support the hypothesis that endosomal NK 1 R signaling underlies sustained neuronal excitation and nociception. Thus, selective antagonism of endosomal receptors could be an effective treatment for pain. To investigate this possibility and to provide direct evidence for the importance of endosomal signaling for nociception, we devised an approach to deliver and concentrate GPCR antagonists in early endosomes. Lipid conjugation anchors drugs at membrane surfaces and promotes endosomal delivery (31) . We synthesized tripartite probes composed of cholestanol (Chol; promotes membrane insertion and anchoring) or ethyl ester (control; no membrane anchoring), a flexible polyethylene glycol (PEG) linker, and a cargo of either cyanine 5 (Cy5) for localization or spantide I (Span), a peptidic membrane-impermeant NK 1 R antagonist (Fig. 6A) (32) . In addition, we synthesized a probe incorporating Span and Cy5 (Span-Cy5-Chol). When incubated with HEK293 cells, Cy5-Chol inserted into the plasma membrane within 5 min, whereas Cy5-ethyl ester remained entirely extracellular ( Fig. 6B and movies S11 and S12). After 4 hours of continuous incubation, Cy5-Chol was concentrated in RAB5A-positive early endosomes, although Cy5-Chol was also detected at the plasma membrane (Fig. 6C ). When incubated with HEK-NK 1 R-green fluorescent protein (GFP) cells for 4 hours, Cy5-Chol also colocalized with NK 1 R-GFP in endosomes (cells were stimulated with SP to induce NK 1 R endocytosis) (Fig. 6C) . When HEK-NK 1 R-GFP cells were pulse-incubated with Cy5-Chol for 30 or 60 min, washed, and allowed to recover for 4 hours, Cy5-Chol was gradually removed from the plasma membrane and accumulated in NK 1 R-GFP-positive endosomes, although some probe remained at the plasma membrane ( fig. S7, A and C) . Cy5-ethyl ester was not taken up by cells after pulse incubation ( fig. S7B ). Quantification of Cy5-Chol uptake after a 30-min pulse incubation indicated that 69% of cell-bound probe was internalized at 4 hours and 79% was internalized at 8 hours after washing ( fig. S7D ). After pulse incubation, Cy5-Span-Chol trafficked to NK 1 R-GFP-positive endosomes (Fig. 6C) . Dy4 inhibited uptake of Chol-conjugated tripartite probes, consistent with constitutive dynamin-mediated endocytosis ( fig. S7E) .
We used FRET to quantify association of tripartite probes with the NK 1 R in endosomes. NK 1 R with extracellular N-terminal SNAP-Tag was expressed in HEK293 cells, and cell surface NK 1 R was labeled with membrane-impermeant SNAP-Surface-549 (SNAP-549). SP (10 nM, 30 min) evoked translocation of SNAP-549-NK 1 R to endosomes (Fig. 6D ). Cells were treated with Cy5-Chol, and FRET between SNAP-549-NK 1 R and Cy5-Chol was measured in regions of interest within the cytosol. Cy5-Chol/SNAP-549-NK 1 R FRET was detected after 5 min and increased for 60 min (Fig. 6, D and E, and movie S13). FRET was not detected in control cells lacking NK 1 R (Fig. 6E) .
Span-Chol antagonized SP [3 nM; 80% effective concentration (EC 80 )]-stimulated Ca 2+ signaling in HEK-NK 1 R cells [minus log of half maximal inhibitory concentration (pIC 50 ), 8.23 ± 0.21 (Span) and 8.44 ± 0.29 (Span-Chol)] and thus retained activity. Because the tripartite probe was concentrated in endosomes after 4 hours, we examined NK 1 R endosomal signaling 4 hours after preincubation with antagonists. When HEK-NK 1 R cells were preincubated with SpanChol, Span, or SR140,333 for 30 min and then immediately challenged with SP, all antagonists blocked nuclear ERK (Fig. 6, F and H) and cytosolic ERK (fig. S8 , A and C) activity, indicating effective antagonism of cell surface NK 1 R. When cells were pulse-incubated with antagonists for 30 min, washed, and stimulated with SP 4 hours later (to allow lipidated antagonists to concentrate in endosomes), Span-Chol alone inhibited nuclear ERK (derives from endosomal NK 1 R) (Fig. 6 , G and H), and no antagonist inhibited cytosolic ERK (derives from plasma membrane NK 1 R) ( fig. S8, B and C) . Span-Chol also prevented SPinduced transcription. HEK-NK 1 R cells were incubated with Span or Span-Chol for 30 min, washed, recovered for 4 hours, and then stimulated with SP for 20 hours. Span-Chol abolished SP-stimulated SRE-SEAP secretion (derives from endosomal NK 1 R), whereas unconjugated Span was ineffective (Fig. 6I) . However, when continuously incubated with antagonists, both Span-Chol and Span inhibited transcription. Span-Chol did not affect isoprenaline-induced activation of nuclear ERK, which is mediated by the endogenous b 2 -adrenergic receptor ( fig. S8D) . Thus, the effects of tripartite antagonists are not mediated by a nonspecific disruption of endosomal signaling.
The results show that lipid conjugation promotes the effective delivery and retention of antagonists to endosomes containing the NK 1 R. After pulse incubation, Span-Chol caused sustained and selective antagonism of endosomal but not plasma membrane NK 1 R. Unconjugated Span and SR140,333, a potent small-molecule antagonist, were unable to effectively inhibit persistent NK 1 R signaling in endosomes.
Endosomally targeted NK 1 R antagonists block nociception
To assess whether antagonism of the endosomal NK 1 R blocks sustained SP-induced excitation of spinal neurons, we incubated slices of rat spinal cord with Span-Chol or Span for 60 min, washed them, and challenged them with SP 60 min later. In vehicle-or Span-treated slices, SP caused brisk firing that was sustained after washout (Fig. 7 , A to C). As observed with endocytic inhibitors, Span-Chol did not suppress the initial excitation but prevented sustained excitation. The SP-induced firing rate (normalized to 2 min, events per 2 min) was 196.6 ± 81.6 for SpanChol and 242.6 ± 95.9 for Span (P < 0.05, ANOVA, Sidak's test).
To evaluate whether endosomal targeting improves the efficacy and duration of action of NK 1 R antagonists for the treatment of pain, we administered cholestanol-conjugated or conventional antagonists by intrathecal injection 3 hours before intraplantar injection of capsaicin. This time was selected to allow endosomal accumulation of lipidated antagonists. When Cy5-Chol was injected intrathecally, probe was detected in laminae I to III neurons after 6 hours, confirming delivery and retention in pain-transmitting neurons (Fig. 7D) . Cy5-Chol did not affect nociception, which excludes nonspecific actions of cholestanol (Fig.  7E) . Span-Chol, but not Span or SR140,333, inhibited capsaicin-evoked mechanical allodynia (Fig. 7E) . When administered 30 min after capsaicin, intrathecal Span was transiently antinociceptive, whereas SpanChol caused a delayed (3 hours), persistent (6 hours), and substantial (>50%) antinociception (Fig. 7F) .
The small-molecule NK 1 R antagonist L-733,060 (33) conjugated to Chol antagonized SP (3 nM; EC 80 )-stimulated Ca 2+ signaling in HEK-NK 1 R cells [% inhibition against 1 nM SP: 40.8 ± 8.9 (10 nM L-733,060) and 71.1 ± 9.2 (10 nM L-733,060-Chol)] and thus retained activity. When injected intrathecally 3 hours before intraplantar capsaicin, L-733,060-Chol was antinociceptive from 1 to 4 hours, whereas L-733,060 was antinociceptive only at 1 hour (Fig. 7G) .
When injected intrathecally 3 hours before intraplantar formalin, Span-Chol inhibited both phases of nocifensive behavior more completely than Span or SR140,333 (Fig. 7H) . When injected intrathecally 36 hours after intraplantar CFA, Span-Chol inhibited mechanical hyperalgesia from 1 to 6 hours, whereas the antinociceptive actions of Span and SR140,333 were minor and transient for Span (Fig. 7, I and J).
The enhanced potency and duration of action of lipidated antagonists could be due to improved metabolic stability rather than to appropriate targeting of endosomal NK 1 R. Membrane peptidases rapidly degrade neuropeptides, including SP, and could also degrade peptidic antagonists (5). Membranes prepared from mouse spinal cord rapidly degraded SP, but not Span or Span-Chol (Fig. 7K) . Span and Span-Chol were also stable in human cerebrospinal fluid (Fig.  7L) . These results suggest that enhanced stability does not account for the sustained antinociceptive actions of cholestanol-conjugated antagonists. 
DISCUSSION
Our results support a reinterpretation of the notion that the primary physiological actions of GPCRs in vivo are mediated by cell surface receptors. By studying the NK 1 R as a prototypical GPCR that traffics to endosomes, we show that endosomal receptors convey sustained signals that underlie excitation and nociceptive transmission in spinal neurons and that targeting these receptors in endosomes is required for optimal pharmacological intervention. We report that endosomal GPCRs generate a spectrum of signals in subcellular compartments. Clathrin and dynamin disruption prevented NK 1 R endocytosis and inhibited activation of nuclear ERK, cytosolic PKC, and cytosolic cAMP. Dynamin inhibitors also blocked SP-induced transcription, which is likely mediated by nuclear ERK. A C-terminally truncated mutant, NK 1 Rd311, was also unable to internalize, activate nuclear ERK, or stimulate transcription. Ga q inhibition blocked NK 1 R endosomal signals, and endosomes contained both activated NK 1 R and Ga q . Our results are consistent with the hypothesis that the NK 1 R in endosomes signals by Ga qdependent processes that activate nuclear ERK, cytosolic PKC, and cytosolic cAMP to cause nociception (Fig. 8A and movie S14). By delivering activated NK 1 R to endosomes and serving as a scaffold for signaling complexes, bARRs facilitate these signals (9, 22, 23) . Our findings add to the growing number of GPCRs, including b 2 -adrenergic and thyroidstimulating hormone receptors (11, 12) , known to signal from endosomes by G proteindependent processes, and provide in vivo evidence that this endosomal mechanism is physiologically relevant.
Together, our findings suggest that endosomal NK 1 R signaling is necessary for sustained excitation of spinal neurons and nociceptive transmission in the spinal cord, reveal a vital link between endosomal signaling and nociception, and provide information about the contribution of clathrin and dynamin to SP-induced excitation of spinal neurons and nociceptive transmission (Fig. 8B) . The observations that dynamin and clathrin inhibitors attenuate NK 1 R endocytosis in spinal neurons and suppress neuronal excitation and nociception are consistent with a role for NK 1 R endocytosis in pain. The finding that selective disruption of NK 1 R-bARR interactions using membrane-permeant peptides and specific antagonism of endosomal NK 1 R with lipidated antagonists effectively suppress neuronal excitation and nociception in several models provides direct support for a major contribution of the endosomal NK 1 R to pain.
The discovery that endosomes are platforms for compartmentalized GPCR signaling that underlies pathophysiologically important processes in vivo has therapeutic implications. Delivery of antagonists to endosomes might facilitate the disruption of sustained signals from endosomal GPCRs that underlie disease and could provide enhanced efficacy and selectivity for treating pain (Fig. 8C) . The accumulation of tripartite probes in NK 1 R-positive endosomes demonstrates the feasibility of endosomal delivery. The capacity of Span-Chol and L-733,060-Chol, but not unconjugated antagonists, to specifically antagonize endosomal NK 1 R signaling and sustained excitation of spinal neurons and to cause prolonged and more effective antinociception demonstrates the importance of endosomal signaling for pain and illustrates the therapeutic utility of endosomally directed drugs.
Limitations of the use of pharmacological inhibitors of endocytosis include the widespread roles of dynamin and clathrin in vesicular transport and synaptic transmission (34, 35) and possible off-target actions of dynamin inhibitors (36) . Thus, the actions of clathrin and dynamin inhibitors on excitation of spinal neurons and on nociceptive behavior might be unrelated to impaired NK 1 R signaling in endosomes and instead due to disrupted endocytosis or exocytosis of other GPCRs, ion channels, and transmitters that control pain transmission, or an artifact of abnormal motor function. However, clathrin and dynamin inhibitors did not affect fast synaptic transmission in the spinal cord or capsaicin-evoked neuropeptide release from spinal terminals of nociceptors and had no effect on motor coordination in vivo. These results suggest that synaptic transmission and vesicular transport were unaffected. The finding that dynamin 1 knockdown in the spinal cord also inhibited nociception suggests that off-target actions of dynamin inhibitors do not account for their antinociceptive properties. The observation that inhibitors of NK 1 R-bARR interactions and lipidated NK 1 R antagonists replicate the antinociceptive effects of endocytosis inhibitors supports a role for NK 1 R signaling in endosomes for nociception. Additional studies will be required to assess the selectivity of peptide inhibitors of NK 1 R-bARR interactions. The antinociceptive actions of lipidated NK 1 R antagonists are unlikely to be related to enhanced stability, given the similar rate of metabolism of unconjugated and cholestanol-conjugated spantide, although detailed pharmacokinetic studies will be required to define the tissue distribution and degradation of lipidated NK 1 R antagonists in vivo. Evaluation of the therapeutic value of cholestanol-conjugated NK 1 R antagonists will require investigation of their potency and efficacy in disease-relevant models of pain. NK 1 R redistributes from the plasma membrane to endosomes in chronic inflammatory and neurological diseases that are associated with persistent SP release (5). We propose that the inability of conventional antagonists to effectively target the NK 1 R in endosomes, where the receptor assembles a multiprotein signalosome in an acidic environment, contributes to their lack of clinical success (5). Our study suggests that therapeutic targeting of endosomal GPCRs is a paradigm of drug delivery that offers more effective and selective treatments for pathophysiological conditions, including chronic pain.
MATERIALS AND METHODS
See the Supplementary Materials for full details of Materials and Methods.
Study design
The study was designed to examine the contribution of SP-induced endocytosis of the NK 1 R to signal transduction in subcellular compartments, excitation of spinal neurons, and nociception. Endocytosis of the NK 1 R was examined in HEK293 cells by using BRET to assess the proximity between the NK 1 R and proteins resident in the plasma membrane and early endosomes and by localizing fluorescent SP by confocal microscopy. BRET was also used to examine the assembly of signaling complexes, which were localized in endosomes by immunofluorescence and super-resolution microscopy. Signaling in subcellular compartments of HEK293 cells was studied by expressing genetically encoded FRET biosensors, which allowed analysis of signaling with high spatial and temporal fidelity. NK 1 R endocytosis was studied in spinal neurons in slice preparations and in vivo by immunofluorescence and confocal microscopy. To examine the excitation of pain-transmitting neurons, cell-attached patch clamp recordings were made from second-order neurons in slices of rat spinal cord. Nociceptive behavior was evaluated in conscious mice after intraplantar administration of capsaicin, formalin, or CFA. To examine the contribution of NK 1 R endocytosis to signaling, neuronal excitation, and nociception, HEK293 cells, rat spinal cord slices, or mice were treated with pharmacological or genetic inhibitors of clathrin, dynamin, or bARRs, or with peptide inhibitors of NK 1 R/bARR interactions. Peptidic and small-molecule antagonists of the NK 1 R were conjugated to the lipid cholestanol, which facilitated endosomal targeting and retention of antagonists. Cholestanolconjugated antagonists were used to directly evaluate the contribution of NK 1 R signaling in endosomes to SP-induced compartmentalized signaling in HEK293 cells, excitation of spinal neurons, and nociception. Institutional Animal Care and Use Committees approved all studies.
Statistical analyses
Data are presented as means ± SEM, unless noted otherwise. Differences were assessed using Student's t test for two comparisons. For multiple comparisons, differences were assessed using one-or twoway ANOVA followed by Dunnett's multiple comparison test, Tukey's multiple comparison test, Sidak's multiple comparisons test, or Dunn's multiple comparisons test. Table S1 provides full details of statistical tests and replicates for each experiment.
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